Riccioni Graziano

Dr. Riccioni Graziano

Studio Medico Polispecialistico, Via Magenta 106, San Severo, 71016 Foggia, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2012 in Marine Drugs
Verified
Journal Article
Open access
PDF file
NDNicolantonio D’orazio
Nicolantonio D’orazio
EGEugenio Gemello
Eugenio Gemello
M.Alessandra GammoneM.Alessandra Gammone
M.Alessandra Gammone
MGMassimo De Girolamo
Massimo De Girolamo
CFCristiana Ficoneri
Cristiana Ficoneri
RGRiccioni Graziano
Riccioni Graziano
The World Health Organization (WHO) estimates that 2.3 billion people will be overweight and 700 million obese in 2015. The reasons for this disastrous trend are attributed to the global tendency toward the reduced magnitude of exercise and physical activity and the increased dietary intake of fats, sugars and calories with reduced amount of vitamins and minerals. To prevent life-style-related diseases, like Metabolic Syndrome (MS), researchers’ attention is increasingly focusing on some of the so called “functional foods” which may be useful for their prevention and treatment. One of these functional ingredients is fucoxanthin (FX), a characteristic carotenoid present in edible brown seaweeds, such as Undaria pinnatifida (Wakame), Hijikia fusiformis (Hijiki), Laminaria japonica (Ma-Kombu) and Sargassum fulvellum. The increasing popularity of this molecule is certainly due to its anti-obesity effect, primarily detected by murine studies. These works revealed FX mediated induction of uncoupling protein-1 (UCP-1) in abdominal white adipose tissue (WAT) mitochondria, leading to the oxidation of fatty acids and heat production in WAT. Beyond this important role, in recent studies FX has shown a great antioxidant activity, anti-cancer, anti-diabetic and anti-photoaging properties. The aim of this review is to highlight the main effects of FX on human health.

30 September 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
M.Alessandra GammoneM.Alessandra Gammone
M.Alessandra Gammone
RGRiccioni Graziano
Riccioni Graziano
NDNicolantonio D'Orazio
Nicolantonio D'Orazio
Carotenoids are lipid-soluble pigments that are produced in some plants, algae, fungi, and bacterial species, which accounts for their orange and yellow hues. Carotenoids are powerful antioxidants thanks to their ability to quench singlet oxygen, to be oxidized, to be isomerized, and to scavenge free radicals, which plays a crucial role in the etiology of several diseases. Unusual marine environments are associated with a great chemical diversity, resulting in novel bioactive molecules. Thus, marine organisms may represent an important source of novel biologically active substances for the development of therapeutics. In this respect, various novel marine carotenoids have recently been isolated from marine organisms and displayed several utilizations as nutraceuticals and pharmaceuticals. Marine carotenoids (astaxanthin, fucoxanthin, β-carotene, lutein but also the rare siphonaxanthin, sioxanthin, and myxol) have recently shown antioxidant properties in reducing oxidative stress markers. This review aims to describe the role of marine carotenoids against oxidative stress and their potential applications in preventing and treating inflammatory diseases.

31 December 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
MCMarco Ciccone
Marco Ciccone
FCFrancesca Cortese
Francesca Cortese
MGMICHELE GESUALDO
MICHELE GESUALDO
SCSanta Carbonara
Santa Carbonara
AZAnnapaola Zito
Annapaola Zito
RGRiccioni Graziano
Riccioni Graziano
Cardiovascular disease related to atherosclerosis represents nowadays the largest cause of morbidity and mortality in developed countries. Due to inflammatory nature of atherosclerosis, several studies had been conducted in order to search for substances with anti-inflammatory activity on arterial walls, able to exert beneficial roles on health. Researches investigated the role of dietary carotenoids supplementation on cardiovascular disease, due to their free radicals scavenger properties and their skills in improving low-density lipoprotein cholesterol resistance to oxidation. Nevertheless, literature data are conflicting: although some studies found a positive relationship between carotenoids supplementation and cardiovascular risk reduction, others did not find any positive effects or even prooxidant actions. This paper aimed at defining the role of carotenoids supplementation on cardiovascular risk profile by reviewing literature data, paying attention to those carotenoids more present in our diet (β-carotene,α-carotene,β-cryptoxanthin, lycopene, lutein, zeaxanthin, and astaxanthin).

5 November 2009 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
RGRiccioni Graziano
Riccioni Graziano

1 August 2007 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RGRiccioni Graziano
Riccioni Graziano
TBT. Bucciarelli
T. Bucciarelli
BMB. Mancini
B. Mancini
CIC. Di Ilio
C. Di Ilio
NDN. D'ORazio
N. D'ORazio
Cysteinyl leukotrienes (Cys-LTs) are potent proinflammatory mediators derived from arachidonic acid through the 5- lypoxigenase (5-LO) pathway. They exert important pharmacological effects by interaction with at least two different receptors: Cys-LT1 and Cys-LT2. By competitive binding to the Cys-LT1 receptor, leukotriene receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast, block the effects of Cys-LTs and alleviate the symptoms of many chronic diseases, especially bronchial asthma and allergic rhinitis. Evidence obtained by randomized clinical trials as also by direct experience derived from patients suffering from asthma and allergic rhinitis justifies a broader role for leukotrienes receptor antagonists (LTRAs). Recently published studies and case reports have demonstrated beneficial effects of LTRAs on other diseases commonly associated with asthma (exercise induced asthma, rhinitis, chronic obstructive pulmonary disease, interstitial lung disease, chronic urticaria, atopic dermatitis, allergic fungal disease, nasal polyposis, and paranasal sinus disease) as well as other diseases not connected to asthma (migraine, respiratory syncytial virus postbronchiolitis, systemic mastocytosis, cystic fibrosis, pancreatitis, vulvovaginal candidiasis, cancer, atherosclerosis, eosinophils cystitis, otitis media, capsular contracture, and eosinophilic gastrointestinal disorders). The aim of this review is to show the most recent applications and effectiveness in clinical practice of the LTRAs.

27 June 2011 in Marine Drugs
Verified
Journal Article
Open access
PDF file
RGRiccioni Graziano
Riccioni Graziano
NDNicolantonio D’orazio
Nicolantonio D’orazio
Sara FranceschelliSara Franceschelli
Sara Franceschelli
Lorenza SperanzaLorenza Speranza
Lorenza Speranza
Marine carotenoids are important bioactive compounds with physiological activities related to prevention of degenerative diseases.found principally in plants, with potential antioxidant biological properties deriving from their chemical structure and interaction with biological membranes. They are substances with very special and remarkable properties that no other groups of substances possess and that form the basis of their many, varied functions and actions in all kinds of living organisms. The potential beneficial effects of marine carotenoids have been studied particularly in astaxanthin and fucoxanthin as they are the major marine carotenoids. Both these two carotenoids show strong antioxidant activity attributed to quenching singlet oxygen and scavenging free radicals. The potential role of these carotenoids as dietary anti-oxidants has been suggested to be one of the main mechanisms for their preventive effects against cancer and inflammatory diseases. The aim of this short review is to examine the published studies concerning the use of the two marine carotenoids, astaxanthin and fucoxanthin, in the prevention of cardiovascular diseases.